Skip to main content
Premium Trial:

Request an Annual Quote

Isis to Gain Almost $4M from Alnylam s Deal with Novartis

NEW YORK, Sept. 12 (GenomeWeb News) - Isis Pharmaceuticals expects nearly $4 million in payments from Alnylam Pharmaceuticals following Alnylam's recent deal with Novartis, the Carlsbad, Calif.-based company said today.


Isissaid it is entitled to a portion of the upfront payments and equity investment from Novartis as part of its 2004 partnership with Alnylam. It might also receive milestone and royalty payments on drugs which utilize technology it licensed to Alnylam.


Under the 2004 agreement, Isislicensed over 150 patents to Alnylam, including the "Crooke" patents that cover mechanisms of RNase-dependent antisense activity and chemically modified oligonucleotides. In exchange, Isisobtained a technology access fee, participation in fees for Alnylam's partnering programs, and downstream milestone and royalty payments.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.